ArticleActa psychiatrica Scandinavica2021
Metabolomic profiles discriminating anxiety from depression.
Article in Acta psychiatrica Scandinavica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active Surveillance.Cancer medicine · 2026Article
- Sex-related molecular phenotypes in anxiety-depressive disorders: a machine learning analysis of routine blood biomarkers.Frontiers in psychiatry · 2026Article
- Advances in understanding intestinal microbiota mechanisms and intervention strategies for anxiety, depression, sleep disorders, and constipation.Frontiers in microbiology · 2026Review
- Metabolomics biomarkers for precision psychiatry.Frontiers in psychiatry · 2026Review
- Quercetin as a Novel Antidepressant: Mechanistic Insights into Its Neuroprotective and Anti-inflammatory Effects.Molecular neurobiology · 2025Article
- Alterations in serum nudifloramide associated with response to diverse pharmacological treatments in major depressive disorder: a preliminary study.Metabolic brain disease · 2025Article
- Artificial Intelligence-Based Methods and Omics for Mental Illness Diagnosis: A Review.Bioengineering (Basel, Switzerland) · 2025Review
- Immunometabolic Pathways: Investigating Mediators of Major Depressive Disorder and Atherosclerotic Cardiovascular Disease Comorbidity.Biological psychiatry global open science · 2025Article
- Psychological and physiological differences related to supportive living situations amongst individuals with physical disabilities.Scientific reports · 2025Article
- Integration of Metabolomic and Brain Imaging Data Highlights Pleiotropy Among Posttraumatic Stress Disorder, Glycoprotein Acetyls, and Pallidum Structure.Biological psychiatry global open science · 2025Article
- Predicting incident cardio-metabolic disease among persons with and without depressive and anxiety disorders: a machine learning approach.Social psychiatry and psychiatric epidemiology · 2025Article
- Morbidity-bridging metabolic pathways: linking early cardiovascular disease risk and depression symptoms using a multi-modal approach.European heart journal open · 2025Article
- Age, Creatinine, and Ejection Fraction (ACEF) Score is Associated with the Presence of Depression and Anxiety Symptoms in PCI Patients.Neuropsychiatric disease and treatment · 2025Article
- Intricate mechanism of anxiety disorder, recognizing the potential role of gut microbiota and therapeutic interventions.Metabolic brain disease · 2024Review
- Systematic identification of the role of gut microbiota in mental disorders: a TwinsUK cohort study.Scientific reports · 2024Article
- A network analysis of depressive symptoms and metabolomics.Psychological medicine · 2023Article
- Metabolomics and Self-Reported Depression, Anxiety, and Phobic Symptoms in the VA Normative Aging Study.Metabolites · 2023Article
- Metabolomics signatures of depression: the role of symptom profiles.Translational psychiatry · 2023Article
- Normal range CAG repeat size variations in the HTT gene are associated with an adverse lipoprotein profile partially mediated by body mass index.Human molecular genetics · 2023Article
- Exploring the role of ketone bodies in the diagnosis and treatment of psychiatric disorders.Frontiers in psychiatry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDepression has been associated with metabolomic alterations. Depressive and anxiety disorders are often comorbid diagnoses and are suggested to share etiology. We investigated whether differential metabolomic alterations are present between anxiety and depressive disorders and which clinical characteristics of these disorders are related to metabolomic alterations.
methodsData were from the Netherlands Study of Depression and Anxiety (NESDA), including individuals with current comorbid anxiety and depressive disorders (N = 531), only a current depression (N = 304), only a current anxiety disorder (N = 548), remitted depressive and/or anxiety disorders (N = 897), and healthy controls (N = 634). Forty metabolites from a proton nuclear magnetic resonance lipid-based metabolomics panel were analyzed. First, we examined differences in metabolites between disorder groups and healthy controls. Next, we assessed whether depression or anxiety clinical characteristics (severity and symptom duration) were associated with metabolites.
resultsAs compared to healthy controls, seven metabolomic alterations were found in the group with only depression, reflecting an inflammatory (glycoprotein acetyls; Cohen's d = 0.12, p = 0.002) and atherogenic-lipoprotein-related (e.g., apolipoprotein B: Cohen's d = 0.08, p = 0.03, and VLDL cholesterol: Cohen's d = 0.08, p = 0.04) profile. The comorbid group showed an attenuated but similar pattern of deviations. No metabolomic alterations were found in the group with only anxiety disorders. The majority of metabolites associated with depression diagnosis were also associated with depression severity; no associations were found with anxiety severity or disease duration.
conclusionWhile substantial clinical overlap exists between depressive and anxiety disorders, this study suggests that altered inflammatory and atherogenic-lipoprotein-related metabolomic profiles are uniquely associated with depression rather than anxiety disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.